Bristol Myers Squibb vs GSK
BMY and GSK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMY and GSK compare
Bristol Myers Squibb grew revenue faster over the last twelve months (4.2% versus 4.1% for GSK).
Bristol Myers Squibb keeps more of each dollar of sales as profit, with a net margin of 18.5% compared with 17.5% at GSK.
Bristol Myers Squibb pays a dividend yielding 4.0%; GSK does not pay one.
Bristol Myers Squibb scores higher on the StockData Score (14 against 9 for GSK), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMY | GSK |
|---|---|---|
| Size and price | ||
| Market cap | $128B | – |
| Share price | $62.48 | $49.51 |
| Change, 1 year | 46.7% | 7.8% |
| Change, 5 years | 5.1% | −7.1% |
| Beta (5Y) | 0.25 | 0.26 |
| Employees | 33K | 500K |
| StockData Score | ||
| Total score | 14 (better) | 9 |
| Valuation score | 4 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 5 (better) | 0 |
| Valuation | ||
| P/E | 13.9× | – |
| P/S | 2.6× | – |
| P/B | 5.5× | – |
| EV/EBITDA | 10.0× | – |
| P/FCF | 13.7× | – |
| PEG | 2.54 | – |
| FCF yield | 7.3% | – |
| Fair value | $87.52 | – |
| Margin of safety | 28.6% | – |
| Growth | ||
| Revenue growth (TTM) | 4.2% (better) | 4.1% |
| Revenue growth, 5Y average | 2.5% | 6.0% (better) |
| Net income growth (TTM) | 53.1% | 122% (better) |
| EPS growth (TTM) | 52.4% | 123% (better) |
| EPS growth, 5Y average | – | −0.54% |
| Profitability | ||
| Gross margin | 69.2% | 72.4% (better) |
| Operating margin | – | 24.3% |
| Net margin | 18.5% (better) | 17.5% |
| FCF margin | 18.6% | 19.6% (better) |
| Return on equity | 44.1% (better) | 38.0% |
| Return on invested capital | – | 23.4% |
| Financial health | ||
| Debt / equity | 1.83 | 1.08 (better) |
| Net debt / EBITDA | 1.92 | 1.40 (better) |
| Interest coverage | – | 11.3× |
| Current ratio | 1.59 (better) | 0.82 |
| Altman Z-score | 2.22 | – |
| Piotroski F-score | 8 | 9 (better) |
| Dividends and buybacks | ||
| Dividend yield | 4.0% | – |
| Payout ratio | 55.4% | 44.9% |
| Years of dividend growth | 16 | – |
| Dividend growth, 5Y average | 6.2% | – |
| Shareholder yield | 4.0% | – |
| Ownership | ||
| Held by institutions | 81.9% | 8.0% |
| Held by insiders | 0.05% | 0.05% |
| Insider net buying, 12 months | −$2.3M | – |
| Superinvestors holding | 2 (better) | 1 |
| Short interest, % of float | 2.2% | – |
Go deeper
- BMY stock overview
- BMY income statement
- BMY valuation and score
- GSK stock overview
- GSK income statement
- GSK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.